Loading...
XNAS
RDHL
Market cap2mUSD
Jul 10, Last price  
0.70USD
Name

Redhill Biopharma Ltd

Chart & Performance

D1W1MN
XNAS:RDHL chart
P/E
—
P/S
7.64
EPS
—
Div Yield, %
—
Shrs. gr., 5y
112.53%
Rev. gr., 5y
-66.15%
Revenues
286k
-96.44%
023,00016,00012,0007,014,0003,000101,0004,007,0008,360,0006,291,00064,359,00085,757,00061,800,0006,530,0008,043,000286,000
Net income
-429k
L-94.81%
-2,544,000-15,503,000-10,326,000-10,628,000-10,711,000-21,090,000-29,370,000-45,544,000-38,820,000-42,304,000-76,173,000-97,744,000-71,669,00023,916,000-8,268,000-429,000
CFO
-10m
L+3.01%
-1,632,000-4,691,000-6,795,000-8,436,000-12,229,000-17,826,000-28,258,000-44,769,000-34,462,000-40,749,000-48,579,000-65,047,000-29,185,000-35,820,000-9,369,000-9,651,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
URL
https://www.redhillbio.com/
IPO date
Feb 01, 2011
Employees
113
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT